Cytokinetics Inc. has disclosed nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) activators reported to be useful for the treatment of cancer, neurodegeneration, mitochondrial and metabolic diseases, cardiovascular, muscle, renal and inflammatory disorders, among others.
Resistance to sorafenib treatment is becoming more common in hepatocellular carcinoma (HCC). Iron is a crucial metal in the mitochondria and is used for synthesis of cofactors that are essential for the correct functioning and cell proliferation.
An article by Daiichi Sankyo Co. Ltd. scientists reports data from a study designed to assess the potential of combining pharmacological inhibition of hematopoietic progenitor kinase 1 (HPK1) with programmed cell death 1 ligand 1 (PD-L1) blockade as a novel strategy to enhance antitumor immunity against tumors with low antigenicity.
Rznomics Inc. has received clinical trial notification (CTN) from Australia’s Therapeutic Goods Administration (TGA) for the initiation of a phase I/IIa trial evaluating RZ-004, a gene therapeutic candidate for autosomal dominant retinitis pigmentosa with rhodopsin mutation.
Immuneage Bio has announced its launch, with $2 million in funding and a focus on rejuvenating the immune system by targeting hematopoietic stem cells (HSCs) residing in the bone marrow.
A team at Massachusetts General Hospital conducted research to evaluate the expression levels of the extracellular matrix protein tubulointerstitial nephritis antigen-like 1 (TINAGL1) in the human ovary.
Delta-like protein 3 (DLL3) is a transmembrane protein overexpressed in the majority of neuroendocrine carcinomas of the lung such as small-cell lung cancer (SCLC). The first DLL3-targeted antibody-drug conjugate (ADC), rovalpituzumab tesirine (Rova-T), led to serious adverse events in clinical testing and its development was discontinued.
Epigenetic desilence of the paternal allele of the gene that causes Angelman syndrome (AS) could be used to treat this disease for which there are currently no approved therapies.
Addex Therapeutics Ltd. has released promising results from its novel γ-aminobutyric acid subtype B receptor (GABA-B) positive allosteric modulator (PAM) chronic cough program. In models of chronic cough in guinea pigs, the candidate GABA-B PAM significantly and dose-dependently reduced citric acid-induced cough frequency and increased cough latency.
The hypothalamus controls several neural circuits that have to do with instinctive behaviors such as food seeking, socialization and offspring maternal care, among others. There is limited knowledge regarding the mechanisms by which internal and external sensory cues are integrated to coordinate innate behavior.
RSS
